Recent advances in the neurobiology of schizophrenia.
Despite great progress in basic schizophrenia research, the conclusive identification of specific etiological factors or pathogenic processes in the illness has remained elusive. The convergence of modern neuroscientific studies in molecular genetics, molecular neuropathology, neurophysiology, in vivo brain imaging, and psychopharmacology, however, indicates that we may be coming much closer to understanding the molecular basis of schizophrenia. Schizophrenia may be a neurodevelopmental and progressive disorder with multiple biochemical abnormalities involving the dopaminergic, serotonin, glutamate, and gamma -aminobutyric acidergic systems. In the near future, biological markers for the illness may come from the combination of diverse assessment techniques. An understanding of the pathophysiology of schizophrenia will be essential to the discovery of preventive measures and therapeutic intervention. Rapidly advancing research into schizophrenia includes diverse etiological hypotheses, and offers directions for future research and treatments.
Miyamoto
Seiya
S
St. Marianna University School of Medicine, Kawasaki 216-8511, Japan.
LaMantia
Anthony S
AS
Duncan
Gary E
GE
Sullivan
Patrick
P
Gilmore
John H
JH
Lieberman
Jeffrey A
JA
D014150:Antipsychotic Agents / Q000494:pharmacology / Q000627:therapeutic use; D015415:Biomarkers; D001921:Brain / Q000473:pathology / Q000503:physiopathology*; D002874:Chromosome Mapping; D004198:Disease Susceptibility; D008040:Genetic Linkage; D020022:Genetic Predisposition to Disease; D014644:Genetic Variation; D006801:Humans; D020411:Oligonucleotide Array Sequence Analysis / Q000379:methods; D012307:Risk Factors; D012559:Schizophrenia / Q000235:genetics* / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology*
D014150:Antipsychotic Agents; D015415:Biomarkers